Search Results (1087)
Documents on Antitrust & Trade Regulation, Pharmaceuticals, Internet & E-Commerce
Show: results per page
|Competition Bureau Releases Updated IP Guidelines|
Jonathan Bitran, Dominic Thérien; McCarthy Tétrault LLP;
October 28, 2014, previously published on October 20, 2014On September 18, 2014, the Competition Bureau (Bureau) released updated Intellectual Property Enforcement Guidelines (IPEGs). These IPEGs are an update of the original guidelines released in 2000 and result from recent consultations; the Bureau has announced that it will soon conduct another...
|FDA Fast-Tracking Experimental Drugs|
McDonald Hopkins LLC;
October 22, 2014, previously published on October 17, 2014The development of a pharmaceutical drug is a slow, deliberate process, and it can take years of back-and-forth between scientists and health officials before medicine makes it to the market.
|DEA Releases Final Rule on Disposal of Controlled Substances|
Duane Morris LLP;
October 3, 2014, previously published on September 26, 2014On September 9, 2014, the U.S. Drug Enforcement Administration (DEA) released notice of a final rule governing the disposal of controlled substances (the "Final Rule"). The Final Rule implements the Secure and Responsible Drug Disposal Act of 2010 (the "Disposal Act"), and...
|Time to Step Up Your COPPA Compliance|
Cynthia J. Larose, Julia M. Siripurapu; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.;
October 3, 2014, previously published on September 25, 2014The Federal Trade Commission (FTC) has made good on its promise to actively enforce the recently amended Children’s Online Privacy Protection Act (COPPA). Here is what you should know about the latest enforcement actions against Yelp and TinyCo and how these might affect your business.
|FDA Issues Draft Guidance Regarding Controlled Correspondence from Generics Manufacturers|
Mintz Levin Cohn Ferris Glovsky Popeo P.C.;
September 18, 2014, previously published on September 9, 2014On August 26, 2014, the FDA issued draft guidance to address “controlled correspondence,” which is the correspondence that generic drug manufacturers submit to the FDA to request information and to clarify issues related to generic drug development, and the FDA’s procedure for...
|FTC Doubles Down in Challenge to Pharmaceutical Settlement|
Paul M. Eckles, Karen Hoffman Lent, Sharis A. Pozen, Steven C. Sunshine; Skadden, Arps, Slate, Meagher & Flom LLP;
September 15, 2014, previously published on September 10, 2014On September 8, 2014, the Federal Trade Commission (FTC) filed a federal antitrust complaint in the United States District Court for the Eastern District of Pennsylvania against defendants AbbVie, Abbott Laboratories, Unimed Pharmaceuticals, Besins Healthcare and Teva Pharmaceuticals alleging...
|Liver Injury Cases Increased Along With Dietary and Herbal Supplement Sales|
Seth A. Katz; Burg Simpson Eldredge Hersh & Jardine, P.C.;
September 11, 2014, previously published on September 5, 2014A new study from researchers in Philadelphia revealed liver damage from dietary and herbal supplements might have increased over the last 10 years. The report "Liver injury from Herbals and Dietary Supplements in the U.S. Drug Induced Liver Injury Network" showed 4 percent of adult...
|Brand-Name Drug Manufacturer Liable For Personal Injuries Caused By Generic Drugs Manufactured By Different Company In Alabama|
Sutherland Asbill Brennan LLP;
September 4, 2014, previously published on August 25, 2014The Supreme Court of Alabama held last week that under Alabama law, a brand-name drug company can be held liable for fraud or misrepresentation based on statements made in connection with the manufacture of a brand-name prescription drug by a plaintiff claiming physical injury cause by a generic...
|Considering Sex-Specific Variation for Personalized Medicine|
Antoinette F. Konski; Foley & Lardner LLP;
September 4, 2014, previously published on September 2, 2014Personalized medicine may use devices and assays that identify sex-related differences. For example, a device or an assay may determine if a cancer patient harboring a particular genetic variance will or will not respond to a particular cancer therapy. In some instances, the prediction of clinical...
|FDA Proposes a New Layer of Regulation for Laboratory Developed Tests|
Caroline M. Tinsley; Baker Sterchi Cowden & Rice, L.L.C.;
September 2, 2014, previously published on August 21, 2014The Food and Drug Administration (FDA) announced its intention to expand the regulation of laboratory developed tests (LDTs). LDTs identify patients’ individual reactions to pharmaceutical treatments, so medical providers can prescribe the best treatment for the particular patient. Unlike...